ATE323482T1 - Verwendung von p38 mapk inhibitoren in der behandlung von augenkrankheiten - Google Patents

Verwendung von p38 mapk inhibitoren in der behandlung von augenkrankheiten

Info

Publication number
ATE323482T1
ATE323482T1 AT00948576T AT00948576T ATE323482T1 AT E323482 T1 ATE323482 T1 AT E323482T1 AT 00948576 T AT00948576 T AT 00948576T AT 00948576 T AT00948576 T AT 00948576T AT E323482 T1 ATE323482 T1 AT E323482T1
Authority
AT
Austria
Prior art keywords
treatment
eye diseases
mapk inhibitors
mapk
mitogen
Prior art date
Application number
AT00948576T
Other languages
English (en)
Inventor
Stuart A Lipton
Original Assignee
Stuart A Lipton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stuart A Lipton filed Critical Stuart A Lipton
Application granted granted Critical
Publication of ATE323482T1 publication Critical patent/ATE323482T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT00948576T 1999-07-02 2000-06-30 Verwendung von p38 mapk inhibitoren in der behandlung von augenkrankheiten ATE323482T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14234199P 1999-07-02 1999-07-02

Publications (1)

Publication Number Publication Date
ATE323482T1 true ATE323482T1 (de) 2006-05-15

Family

ID=22499482

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00948576T ATE323482T1 (de) 1999-07-02 2000-06-30 Verwendung von p38 mapk inhibitoren in der behandlung von augenkrankheiten

Country Status (9)

Country Link
US (1) US20030078274A1 (de)
EP (1) EP1196167B1 (de)
JP (1) JP2003503456A (de)
AT (1) ATE323482T1 (de)
AU (1) AU777275B2 (de)
CA (1) CA2373883A1 (de)
DE (1) DE60027431T2 (de)
ES (1) ES2260033T3 (de)
WO (1) WO2001001986A1 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100525768C (zh) * 2000-10-23 2009-08-12 史密丝克莱恩比彻姆公司 新化合物
AR035971A1 (es) * 2001-05-16 2004-07-28 Cephalon Inc Metodos para el tratamiento y la prevencion del dolor
US20050080113A1 (en) * 2001-06-11 2005-04-14 Shigenori Ohkawa Medicinal compositions
EP1709965A3 (de) 2001-07-11 2006-12-27 Boehringer Ingelheim Pharmaceuticals, Inc. Methode zur Behandlung von zytokinvermittelten Erkrankungen
US20040242545A1 (en) * 2001-07-26 2004-12-02 Santen Phamaceutical Co., Ltd. Remedy for glaucoma comprising as the active ingredient compound having p13 kinase inhibitory effect
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
UA80295C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
US20040087558A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
WO2004064733A2 (en) * 2003-01-15 2004-08-05 Board Of Regents, University Of Texas System The use of c-raf inhibitors for the treatment of neurodegenerative diseases
EP2295433A3 (de) * 2003-03-06 2011-07-06 Eisai R&D Management Co., Ltd. JNK Inhibitoren
WO2005000295A1 (en) * 2003-05-20 2005-01-06 Transtech Pharma, Inc. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
EP1493438A1 (de) * 2003-07-03 2005-01-05 Bayer HealthCare AG Inhibitoren des Vanilloid-Rezeptors (VR1) zur Behandlung von HIV-bedingten Schmerz
US7749999B2 (en) 2003-09-11 2010-07-06 Itherx Pharmaceuticals, Inc. Alpha-ketoamides and derivatives thereof
US20100113481A1 (en) * 2003-12-17 2010-05-06 Alcon Research, Ltd. Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
US7662389B2 (en) * 2003-12-17 2010-02-16 Alcon, Inc. Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
GB0330042D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
GB0330043D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
EP2311837B1 (de) 2004-03-30 2014-05-21 Vertex Pharmaceuticals Inc. Als Inhibitoren von jak und anderen Proteinkinasen geeignete Azaindole
WO2005120496A2 (en) * 2004-05-24 2005-12-22 Regents Of The University Of California TREATING LEARNING DEFICITS WITH INHIBITORS OF HMG CoA REDUCTASE
PL1781315T3 (pl) 2004-08-23 2015-08-31 Yeda Res & Dev Inhibitory peptydowe do pośredniczenia w odpowiedziach na stres
CA2599449A1 (en) * 2005-02-28 2006-08-31 Merckle Gmbh 2-sulfinyl- and 2-sulfonyl-substituted imidazole derivatives and their use as cytokine inhibitors
NZ562433A (en) * 2005-03-25 2010-12-24 Glaxo Group Ltd Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives, and their precursors
UY29440A1 (es) * 2005-03-25 2006-10-02 Glaxo Group Ltd Nuevos compuestos
US7473784B2 (en) 2005-08-01 2009-01-06 Bristol-Myers Squibb Company Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
TW200804345A (en) 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
JP5591471B2 (ja) 2006-01-17 2014-09-17 バーテックス ファーマシューティカルズ インコーポレイテッド ヤヌスキナーゼ阻害剤として有用なアザインドール
MX2008013427A (es) 2006-04-19 2008-11-04 Novartis Ag Compuestos de benzoxazole y benzotiazole sustituidos-6-0 y metodos para inhibir la señalizacion csf-1r.
US20090252717A1 (en) * 2006-05-26 2009-10-08 Scott Thomas Brady Compositions and Methods for Treating Polyglutamine-Expansion Neurodegenerative Diseases
GB0612026D0 (en) * 2006-06-16 2006-07-26 Smithkline Beecham Corp New use
US20100069409A1 (en) * 2006-06-16 2010-03-18 Glaxo Group Limited "novel compounds"
JP2009542818A (ja) * 2006-06-16 2009-12-03 グラクソ グループ リミテッド 新規化合物
ES2301380B1 (es) 2006-08-09 2009-06-08 Laboratorios Almirall S.A. Nuevos derivados de 1,7-naftiridina.
JP5406039B2 (ja) 2006-12-21 2014-02-05 バーテックス ファーマシューティカルズ インコーポレイテッド タンパク質キナーゼ阻害剤として有用な５−シアノ−４−（ピロロ［２，３ｂ］ピリジン−３−イル）−ピリミジン誘導体
ES2320955B1 (es) 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
ES2329639B1 (es) 2007-04-26 2010-09-23 Laboratorios Almirall S.A. Nuevos derivados de 4,8-difenilpoliazanaftaleno.
EP2108641A1 (de) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. Neue substituierte Spiro[Cycloalkyl-1,3'-indo]-2'(1'H)-on-Derivate und ihre Verwendung als p38 mitogen-activated Kinase Inhibitoren
EP2113503A1 (de) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. Neue substituierte Indolin-2-on- Derivate und ihre Verwendung als p39 mitogen-activated Kinase Inhibitoren
DE102008029072A1 (de) * 2008-06-10 2009-12-17 Lang, Florian, Prof. Dr.med. Sgk3 als therapeutisches und diagnostisches Target für Alterserkrankungen
KR101204108B1 (ko) * 2009-02-09 2012-11-22 주식회사 지엔티파마 5-벤질아미노살리실산 유도체 또는 이의 염의 의약 용도
NZ597059A (en) 2009-06-17 2014-01-31 Vertex Pharma Inhibitors of influenza viruses replication
EP2322176A1 (de) 2009-11-11 2011-05-18 Almirall, S.A. Neue 7-Phenyl-[1,2,4]triazol[4,3-a]pyridin-3(2H)on-Derivate
CN102858748B (zh) * 2010-04-28 2015-06-17 东丽株式会社 阿尔茨海默病的治疗剂或预防剂
US20120245188A1 (en) * 2010-11-15 2012-09-27 Translational Genomics Research Institute Methods of treating memory loss and enhancing memory performance
RU2013132681A (ru) 2010-12-16 2015-01-27 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы репликации вирусов гриппа
WO2012160563A2 (en) 2011-05-23 2012-11-29 Yeda Research And Development Co. Ltd. Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
WO2013086002A1 (en) * 2011-12-05 2013-06-13 Cellworks Research India Private Limited Compositions, process of preparation of said compositions and method of treating cancer
EP2843049B1 (de) * 2012-04-27 2018-04-11 Keio University Promoter für neuronale differenzierung
WO2014145485A2 (en) 2013-03-15 2014-09-18 The Trustees Of Columbia University In The City Of New York Map kinase modulators and uses thereof
HUE052178T2 (hu) 2013-11-13 2021-04-28 Vertex Pharma Eljárások influenzavírus-replikáció inhibitorainak elõállítására
SG10201804026WA (en) 2013-11-13 2018-06-28 Vertex Pharma Inhibitors of influenza viruses replication
MA42422A (fr) 2015-05-13 2018-05-23 Vertex Pharma Inhibiteurs de la réplication des virus de la grippe
WO2016183116A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
US10702589B2 (en) * 2016-10-04 2020-07-07 Ann And Robert H. Lurie Children's Hospital Of Chicago Compositions and methods of treating neurological disorder and stress-induced conditions
US11891382B2 (en) 2017-04-26 2024-02-06 Basilea Pharmaceutica International AG Processes for the preparation of furazanobenzimidazoles and crystalline forms thereof
CN116617224A (zh) * 2023-05-04 2023-08-22 上海交通大学医学院附属瑞金医院 OPN和p38 MAPK信号通路靶向调控剂在制备神经退行性疾病药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6147080A (en) * 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US6093742A (en) * 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
WO1999061039A2 (en) * 1998-05-22 1999-12-02 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Novel composition for modulating ischemic cell death
US6288089B1 (en) * 1998-12-21 2001-09-11 Michael Zawada Use of kinase inhibitors for treating neurodegenerative diseases

Also Published As

Publication number Publication date
EP1196167B1 (de) 2006-04-19
DE60027431D1 (de) 2006-05-24
US20030078274A1 (en) 2003-04-24
EP1196167A4 (de) 2003-05-02
CA2373883A1 (en) 2001-01-11
ES2260033T3 (es) 2006-11-01
AU777275B2 (en) 2004-10-07
AU6205200A (en) 2001-01-22
EP1196167A1 (de) 2002-04-17
DE60027431T2 (de) 2007-07-12
WO2001001986A1 (en) 2001-01-11
JP2003503456A (ja) 2003-01-28

Similar Documents

Publication Publication Date Title
DE60027431D1 (de) Verwendung von p38 MAPK Inhibitoren in der Behandlung von Augenkrankheiten
ATE362363T1 (de) Verwendung von tnf-alpha inhibitoren zur behandlung von nervenwurzelschäden
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE69616376D1 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
ATE361752T1 (de) Methoden zur prophylaxe und behandlung von schäden der wahrnehmungshärchenzellen und der cochlearen neuronen
ATE211129T1 (de) Inhibitoren von beta-amyloid-protein-herstellung
ATE381935T1 (de) Verwendung von triacetyluridin zur behandlung von mitochondrialen erkrankungen
DE69521620D1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
NO20025104L (no) Inhibitorer av human fosfatidyl-inositol-3-kinase delta
EA200200847A1 (ru) Производные пиперазина и пиперидина для лечения и профилактики поврежденных нейронов
ATE154758T1 (de) Levobupivacain nützlich zur behandlung von chronischen schmerzen
ATE365550T1 (de) Verwendung von einem protein kinase hemmer wie z.b. genistein bei der behandlung von diabetischer retinopathie
ATE329588T1 (de) Verwendung von sibutramin zur behandlung von von organischen störungen verursachten zns- erkrankungen
DE60008753D1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
DE60130872D1 (de) Verfahren und mittel zur behandlung und vorbeugung von erkrankungen der hinteren augenkammer
DE602004021847D1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
DE69900847D1 (de) Map kinase-inhibitoren zur behandlung von durch tnf-alpha induzierte lipolyse- verursachte krankheiten
DE69431199D1 (de) Melatonin-Derivate zur Verwendung in der Behandlung von Schlafstörungen
ATE239470T1 (de) Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen
DE69912304D1 (de) Verwendung von staurosporine derivaten zur behandlung von okularen neovaskularen erkrankungen
DE59907195D1 (de) Verfahren zur behandlung von erkrankungen oder störungen des innenohrs
DE60326742D1 (de) Piperazin und piperadin-derivate für die behandlung von neurologischen krankheiten
ATE214605T1 (de) Verwendung von eliprodil zur herstellung eines arzneimittels zur behandlung von ischämischen störungen der retina oder des sehnervs
ATE428470T1 (de) Heilmittel zur behandlung von erkrankungen des sehnervs

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties